Helicobacter pylori infection
Conditions
Interventions
VHKA:vonoprazan 20mg bid,amoxicillin(Hunan Kelun) 1g tid for 14 days
VHLA:vonoprazan 20mg bid,amoxicillin(Zhuhai Federation) 1g tid for 14 days
Sponsors
Lanzhou University Second Hospital
Eligibility
Sex/Gender
All
Age
17 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1 Age: 17~70 years old, male or female. 2 Confirmed Helicobacter pylori infection (positive 13C/14C-urea breath test). 3 People who have been eradicated for the first time (who have received eradication therapy for HP infection for the first time) and people who have been eradicated for the second time (who have continued treatment after the failure of eradication therapy for HP infection for the first time). 4 No penicillin allergy. 5 The study subject voluntarily joins this trial, understands and agrees to follow the requirements of the study. Informed consent signed by the patient or his/her legal representative.
Exclusion criteria
Exclusion criteria: 1 Use of drugs that may affect the results of the study within four weeks before treatment (including PPIs, potassium competitive acid blockers, antibiotics, H2 receptor antagonists, bismuth agents, probiotic preparations, traditional Chinese medicine, etc.). 2 Individuals who are allergic to amoxicillin or vornoraxen or have contraindications. 3 Presence of other serious diseases that affect the evaluation of this study. (e.g., severe systemic disease, liver and kidney dysfunction, malignant gastrointestinal tumors) 4 Previous upper gastrointestinal surgery. 5 Concurrent use of non-steroidal anti-inflammatory drugs, adrenocorticosteroids, anticoagulants, and alcoholism during treatment. 6 Pregnant, lactating, or planning to become pregnant. 7 Difficulty in completing follow-up or presence of other factors affecting adherence 8 Have participated in other clinical studies within 3 months of this trial or are participating in other clinical studies. 9 Patients with previous failed Helicobacter pylori eradication regimen including amoxicillin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of helicobacter pylori eradication rate;Cost-effectiveness analysis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of incidence of adverse reactions;Gastrointestinal Symptom Improvement Rate;Comparison of compliance;Factors influencing eradication rate;Changes in Gut Microbiota; | — |
Countries
China
Contacts
Public ContactDe-Kui Zhang
Lanzhou University Second Hospital
Outcome results
None listed